InDex Pharmaceuticals

Industry / private company


Location: Stockholm, Sweden (SE) SE

ISNI: -

ROR: https://ror.org/05225cn18

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial (2020) Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, et al. Journal article Cobitolimod for Moderate-to-Severe Left-Sided Ulcerative Colitis (CONDUCT): A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial (2020) Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, et al. Conference contribution The TLR9 agonist cobitolimod induces IL10 producing wound healing macrophages and regulatory T cells in ulcerative colitis (2020) Schmitt H, Ulmschneider J, Billmeier U, Scarozza P, Sonnewald S, Reid S, Atreya I, et al. Journal article, Original article Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis (2018) Atreya R, Reinisch W, Peyrin-Biroulet L, Scaldaferri F, Admyre C, Knittel T, Kowalski J, et al. Journal article The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in ulcerative colitis (2018) Schmitt H, Billmeier U, Ulmschneider J, Admyre C, Knittel T, Zargari A, Neurath M, Atreya R Conference contribution IL-10 induction properties of the TLR-9 agonist cobitolimod - a candidate for treatment of active ulcerative colitis in late stage of clinical development (2017) Admyre C, Zargari A, Atreya R, Knittel T Conference contribution Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis (2016) Atreya R, Bloom S, Scaldaferri F, Gerardi V, Admyre C, Karlsson A, Knittel T, et al. Journal article